在儿科膀炎中使用阿达利穆马布单疗法或与甲酸联合疗法:来自AIDA网络膀炎注册表的数据
Carla Gaggiano1, Alejandra de-la-Torre2, Silvana Guerriero3
1Rheumatology Unit, Department of Medical Sciences, Surgery and Neuroscience, University of Siena, Siena University Hospital [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Siena, Italy.
Clinical & experimental ophthalmology
|April 4, 2025
概括
在治疗儿科非传染性脑膜炎 (NIU) 方面,阿达利穆马布 (ADA) 单一疗法与甲醇 (MTX) 联合疗法同样有效. 这两种治疗方法都能减少复发并保持视力敏,具有类似的长期保留率.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 儿科 儿科 儿科
背景情况:
- 儿童非传染性脑膜炎 (NIU) 需要有效的治疗,以防止视力丧失.
- 阿达利穆马布 (ADA) 是一种用于NIU的生物药物,但其最佳用途 (单疗与组合疗法) 正在调查中.
研究的目的:
- 为了比较Adalimumab (ADA) 单一疗法的疗效与ADA与甲醇 (MTX) 结合治疗儿科非传染性脑膜炎 (NIU) 的疗效.
主要方法:
- 一项基于注册表的观察性研究包括使用ADA治疗的活跃NIU的儿童.
- 患者被分为两组:ADA单一治疗和ADA加MTX组合治疗.
- 通过控制紫外线炎,复发率,视力敏度和类固醇节约效应来评估有效性.
主要成果:
- 分析了84名儿童,其中22名在ADA单疗组和62名在ADA加MTX组.
- 总体有效性 (完全,部分,缺席) 在不同组之间没有显著差异 (p=0.89).
- 这两种治疗策略都显著减少了脑膜炎复发,并证明了类固醇缓解效果,具有可比的最终视力敏度和最长36个月的ADA保留率.
结论:
- 在治疗儿科NIU时,Adalimumab单一治疗似乎与甲铁酸联合治疗一样有效.
- 这两种方法在预防复发,保持视力敏和维持治疗坚持方面都显示出相似的有效性.
- 需要进一步的研究,以充分定义ADA单疗法在儿科NIU的治疗策略中的作用.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
109
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
109
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
103
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
103
01:29Inflammatory Bowel Disease IV: Pharmacological Management
82
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
82
01:29Drugs for Treatment of Ulcerative Colitis in IBD
110
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
110
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
91
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
91